PRESS RELEASE published on 08/14/2024 at 14:00, 2 years 2 months ago Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q2 2024, focusing on DNase-based oncology program in preclinical studies with data due before year end. Ended quarter with $7.3M cash Financial Results Xenetic Biosciences Cash Balance DNase-based Oncology Program Preclinical Studies
BRIEF published on 05/22/2024 at 23:05, 2 years 5 months ago Xenetic Biosciences, Inc. annonce une transition de direction Développement Clinique Oncologie Leadership Executif Biosciences Xénétiques James Parslow
BRIEF published on 05/22/2024 at 23:05, 2 years 5 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences Oncology Clinical Development Executive Leadership James Parslow
PRESS RELEASE published on 05/22/2024 at 23:00, 2 years 5 months ago Xenetic Biosciences, Inc. Announces Executive Leadership Transition Xenetic Biosciences appoints James F. Parslow as interim CEO. The company focuses on innovative immune-oncology technologies for hard-to-treat cancers Xenetic Biosciences Clinical Development Pancreatic Carcinoma James Parslow Immune-oncology Technologies
BRIEF published on 05/10/2024 at 14:35, 2 years 5 months ago Xenetic Biosciences publie ses résultats financiers et ses progrès commerciaux pour le premier trimestre 2024 Résultats Financiers Biosciences Xénétiques Programme D'oncologie Thérapie Basée Sur La DNase Etudes Précliniques
BRIEF published on 05/10/2024 at 14:35, 2 years 5 months ago Xenetic Biosciences Reports Q1 2024 Financial Results and Business Progress Financial Results Xenetic Biosciences Oncology Program DNase-based Therapy Preclinical Studies
PRESS RELEASE published on 05/10/2024 at 14:30, 2 years 5 months ago Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Xenetic Biosciences, Inc. reports financial results for Q1 2024 and progress on DNase-based oncology program, including ongoing preclinical studies and funds of $7.8 million Financial Results Xenetic Biosciences DNase-based Oncology Program Preclinical Studies Cash Reserves
BRIEF published on 03/22/2024 at 13:05, 2 years 7 months ago Xenetic Biosciences, Inc. présente ses performances financières et ses progrès en matière de développement pour l'année 2023 Résultats Financiers Produits Biopharmaceutiques Biosciences Xénétiques Programme D'oncologie Plateforme DNase
BRIEF published on 03/22/2024 at 13:05, 2 years 7 months ago Xenetic Biosciences, Inc. Presents Full Year 2023 Financial Performance and Development Progress Financial Results Xenetic Biosciences Biopharmaceuticals Oncology Program DNase Platform
PRESS RELEASE published on 03/22/2024 at 13:00, 2 years 7 months ago Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results Xenetic Biosciences reports financial results for 2023, highlighting progress on DNase-based oncology program leading to Phase 1 study for pancreatic carcinoma & solid tumors, ending year with $9.0 million Financial Results Xenetic Biosciences Solid Tumors DNase-based Oncology Program Pancreatic Carcinoma
Published on 11/04/2026 at 23:10, 2 hours 27 minutes ago Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 2 hours 37 minutes ago Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 3 hours 22 minutes ago Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 3 hours 32 minutes ago Stabilis Solutions Announces Third Quarter 2026 Results
Published on 11/05/2026 at 00:02, 1 hour 35 minutes ago EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Published on 11/04/2026 at 19:41, 5 hours 56 minutes ago EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 6 hours 12 minutes ago Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 6 hours 54 minutes ago EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 7 hours 32 minutes ago Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 18:00, 7 hours 37 minutes ago The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 7 hours 37 minutes ago L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:44, 7 hours 53 minutes ago Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026
